48 results on '"Samukawa, Y."'
Search Results
2. Sodium-glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low-carbohydrate diet.
- Author
-
Nishimura, R., Omiya, H., Sugio, K., Ubukata, M., Sakai, S., and Samukawa, Y.
- Subjects
GLUCOSE ,GLYCEMIC control ,LOW-carbohydrate diet ,TYPE 2 diabetes ,HYPOGLYCEMIA ,HYPOGLYCEMIC agents - Abstract
This randomized, double-blind, placebo-controlled, crossover study was the first to determine the effects of luseogliflozin in combination with a low-carbohydrate diet ( LCD) on 24-h glucose variability, assessed by continuous glucose monitoring ( CGM). A total of 18 Japanese patients with type 2 diabetes were randomized into two groups, in which patients first received luseogliflozin 2.5 mg once daily then placebo for 8 days each, or vice versa. Patients took luseogliflozin or placebo with a normal-carbohydrate diet ( NCD) on day 7 and with the LCD on day 8. CGM was performed on both days. Luseogliflozin significantly reduced glucose exposure in terms of the area under the curve over the course of 24 h when administered with the NCD (difference vs placebo: −555.6 mg/dl·h [1 mg/dl = 0.0556 mmol/l]; p < 0.001) or with the LCD (−660.7 mg/dl·h; p < 0.001). No hypoglycaemia was observed over 24 h with either diet. Although glucose levels were lower with the LCD than with the NCD in the placebo treatment period, luseogliflozin with the LCD improved glycaemic control throughout the day to nearly the same extent as luseogliflozin with the NCD, without inducing hypoglycaemia. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
3. PO426 EFFICACY AND SAFETY OF LUSEOGLIFLOZIN IN VARIOUS LEVELS OF RENAL FUNCTION IN JAPANESE PATIENTS WITH TYPE 2 DIABETES MELLITUS: ANALYSIS OF POOLED DATA FROM LONG-TERM PHASE 3 TRIALS.
- Author
-
Ubukata, M., Samukawa, Y., Sakai, S., Sasaki, T., Haneda, M., Inagaki, N., Kaku, K., and Seino, Y.
- Subjects
- *
TYPE 2 diabetes treatment , *DRUG efficacy , *MEDICATION safety , *SORBITOL , *KIDNEY physiology , *JAPANESE people , *CLINICAL trials , *DISEASES - Published
- 2014
- Full Text
- View/download PDF
4. PO425 EFFICACY AND SAFETY OF LUSEOGLIFLOZIN IN JAPANESE PATIENTS WITH TYPE 2 DIABETES MELLITUS BASED ON BMI: ANALYSIS OF POOLED DATA FROM LONG-TERM PHASE 3 TRIALS.
- Author
-
Sakai, S., Ubukata, M., Samukawa, Y., Sasaki, T., Haneda, M., Inagaki, N., Kaku, K., and Seino, Y.
- Subjects
- *
TYPE 2 diabetes treatment , *DRUG efficacy , *MEDICATION safety , *JAPANESE people , *BODY mass index , *CLINICAL trials , *DISEASES - Published
- 2014
- Full Text
- View/download PDF
5. PO433 EFFICACY AND SAFETY OF LUSEOGLIFLOZIN IN YOUNGER AND ELDERLY JAPANESE PATIENTS WITH TYPE 2 DIABETES MELLITUS: ANALYSIS OF POOLED DATA FROM LONG-TERM PHASE 3 TRIALS.
- Author
-
Ubukata, M., Sakai, S., Samukawa, Y., Sasaki, T., Haneda, M., Inagaki, N., Kaku, K., and Seino, Y.
- Subjects
- *
DIABETES , *TYPE 2 diabetes treatment , *DAPAGLIFLOZIN , *JAPANESE people , *MEDICAL databases , *CLINICAL trials , *THERAPEUTICS , *DISEASES - Published
- 2014
- Full Text
- View/download PDF
6. Age-related differences in olfactory profiles and surgical outcomes in eosinophilic chronic rhinosinusitis.
- Author
-
Akiyama K, Arakawa Y, Samukawa Y, and Hoshikawa H
- Subjects
- Humans, Chronic Disease, Adult, Middle Aged, Female, Male, Treatment Outcome, Age Factors, Aged, Smell, Rhinosinusitis, Sinusitis surgery, Sinusitis diagnosis, Rhinitis surgery, Rhinitis diagnosis, Eosinophilia
- Published
- 2024
- Full Text
- View/download PDF
7. Is the measurement of ethmoid sinus dominance in eosinophilic chronic rhinosinusitis accurate?
- Author
-
Akiyama K, Samukawa Y, and Hoshikawa H
- Subjects
- Humans, Chronic Disease, Female, Male, Middle Aged, Adult, Severity of Illness Index, Aged, Eosinophilia diagnostic imaging, Young Adult, Endoscopy, Reproducibility of Results, Adolescent, Rhinosinusitis, Ethmoid Sinus diagnostic imaging, Sinusitis diagnostic imaging, Sinusitis surgery, Rhinitis diagnostic imaging, Rhinitis surgery, Tomography, X-Ray Computed
- Abstract
Objective: An ethmoid-dominant shadow on computed tomography is an indicator of type 2 inflammation, and is one of the main items used to diagnose and classify the severity of eosinophilic chronic rhinosinusitis in the Japanese diagnostic criteria. Ethmoid sinus dominance is examined using the Lund-Mackay scoring system and may be overestimated due to scoring characteristics. We aim to investigate the accuracy of evaluations of ethmoid dominance using the conventional scoring system and the possibility of conducting an objective evaluation using a more detailed other scoring system., Methods: Patients diagnosed with eosinophilic chronic rhinosinusitis and who underwent bilateral endoscopic sinus surgery were enrolled in the present study. Computed tomography was performed preoperatively on all subjects. The bilateral anterior and posterior ethmoid sinuses and bilateral maxillary sinus were scored, and the ethmoid-to-maxillary ratio was calculated using 3 different scoring systems: Lund-Mackay (each sinus score ranges between 0 and 2), simplified Zinreich (score ranging between 0 and 3), and Zinreich (score ranging between 0 and 5)., Results: A total of 149 patients were eligible for the present study. Significant differences were observed in ethmoid-to-maxillary ratio evaluated by the 3 different scoring systems (2.4 ± 0.7, 3.0 ± 1.1, and 3.7 ± 2.2). Only 2 patients were negative for ethmoid dominance by the Lund-Mackay scoring system, while 14 were negative by the simplified-Zinreich and Zinreich scoring systems. Severity changed from the initial grade in 12 patients., Conclusions: The present results confirmed a potential overestimation when only the Lund-Mackay scoring system was used to assess ethmoid dominance. Ethmoid dominance has been identified as one of the main predictive factors for the long-term postoperative outcomes of eosinophilic chronic rhinosinusitis and is included in the Japanese diagnostic criteria. A detailed evaluation of ethmoid dominance is desirable for more accurate evaluations of the severity and prognosis of eosinophilic chronic rhinosinusitis., (Copyright © 2024 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier España S.L.U. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
8. The flavonoid Sudachitin regulates glucose metabolism via PDE inhibition.
- Author
-
Hatanaka R, Taguchi A, Nagao Y, Yorimoto K, Takesato A, Masuda K, Ono T, Samukawa Y, Tanizawa Y, and Ohta Y
- Abstract
Sudachitin, a member of the flavonoid family, reportedly improves glucose metabolism after long-term administration, but details of the underlying mechanisms are unknown. We found that Sudachitin approximately doubles insulin secretion under high glucose concentrations in mouse pancreatic islets and MIN6 cells. When Sudachitin was orally administered to mice, early-phase insulin secretion was increased and a 30 % reduction in blood glucose levels was demonstrated 30 min after glucose loading. Insulin tolerance tests also showed Sudachitin to increase systemic insulin sensitivity. Additionally, we observed that Sudachitin raised intracellular cAMP levels in pancreatic islets. Phosphodiesterase (PDE) activity assays revealed Sudachitin to inhibit PDE activity and computer simulations predicted a high binding affinity between PDEs and Sudachitin. These findings suggest that Sudachitin enhances both insulin secretion and insulin sensitivity via an increase in intracellular cAMP resulting from PDE inhibition. These insights may facilitate understanding the mechanisms underlying the regulation of glucose metabolism by Sudachitin and other isoflavones., Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Akihiko Taguchi reports financial support was provided by Taisho Pharmaceutical Co., Ltd. Akihiko Taguchi reports financial support was provided by the 10.13039/501100001691Japan Society for the Promotion of Science. Akihiko Taguchi reports financial support was provided by 10.13039/501100011907Mishima Kaiun Memorial Foundation. Yasuharu Ohta reports financial support was provided by the 10.13039/501100001691Japan Society for the Promotion of Science. Yukio Tanizawa reports financial support was provided by the 10.13039/501100001691Japan Society for the Promotion of Science. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2024 The Authors.)
- Published
- 2024
- Full Text
- View/download PDF
9. Systemically Administered D-allose Inhibits the Tumor Energy Pathway and Exerts Synergistic Effects With Radiation.
- Author
-
Samukawa Y, Ouchi Y, Miyashita T, Rahman A, Tsukamoto I, Yoshihara A, and Hoshikawa H
- Subjects
- Animals, Humans, Male, Mice, AMP-Activated Protein Kinases metabolism, Carrier Proteins genetics, Carrier Proteins metabolism, Cell Line, Tumor, Cell Proliferation drug effects, Energy Metabolism drug effects, Glycolysis drug effects, Mice, Nude, Xenograft Model Antitumor Assays, Glucose metabolism, Head and Neck Neoplasms pathology, Head and Neck Neoplasms metabolism, Head and Neck Neoplasms drug therapy, Head and Neck Neoplasms radiotherapy, Head and Neck Neoplasms genetics
- Abstract
Background/aim: The present study investigated the anticancer effects of intraperitoneally administered D-allose in in vivo models of head and neck cancer cell lines., Materials and Methods: To assess the direct effects of D-allose, its dynamics in blood and tumor tissues were examined., Results: D-allose was detected in blood and tumor tissues 10 min after its intraperitoneal administration and then gradually decreased. In vivo experiments revealed that radiation plus D-allose was more effective than either treatment alone. Thioredoxin-interacting protein (TXNIP) mRNA over-expression was detected after the addition of D-allose in in vitro and in vivo experiments. D-allose inhibited cell growth, which was associated with decreases in glycolysis and intracellular ATP levels and the prolonged activation of AMPK. The phosphorylation of p38-MAPK was also observed early after the administration of D-allose and was followed by the activation of AMPK and up-regulated expression of TXNIP in both in vitro and in vivo experiments., Conclusion: Systemically administered D-allose appears to exert antitumor effects. Further studies are needed to clarify the appropriate dosage and timing of the administration of D-allose and its combination with other metabolic agents., (Copyright © 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
10. Assessment of eosinophilic rhinosinusitis cases that required secondary treatment (biologics or reoperation) during long-term postoperative courses.
- Author
-
Akiyama K, Samukawa Y, and Hoshikawa H
- Subjects
- Humans, Reoperation, Retrospective Studies, Chronic Disease, Endoscopy methods, Rhinosinusitis, Biological Products, Rhinitis surgery, Rhinitis complications, Sinusitis surgery, Sinusitis complications, Nasal Polyps surgery
- Abstract
Objective: Endoscopic sinus surgery (ESS) is selected as the primary treatment for eosinophilic chronic rhinosinusitis (ECRS). Biologics or reoperation are sometimes required as secondary treatment after ESS. The present study examined the long-term postoperative courses of ECRS cases treated according to the current treatment concept, the frequency of secondary treatment, and its predictive factors., Methods: Ninety-four patients with ECRS who underwent ESS and received continuous management for 1-5 years were retrospectively investigated. Patient characteristics, long-term changes in endoscopic scores and the results of olfactory function tests, and secondary treatment were evaluated., Results: Five patients underwent reoperation and 11 received dupilumab during the follow-up period (35.9±19.2 months). Sixteen patients (17%) required secondary treatment due to the deterioration of sinus conditions. These patients were significantly younger, had higher comorbidity rates of allergic rhinitis and bronchial asthma, and a higher preoperative CT score than those who did not require secondary treatment. Three months after surgery, CT scores, endoscopic scores (E-scores), and the self-administered odor questionnaire (SAOQ) were significantly worse in patients who required secondary treatment. A multivariate regression analysis identified age, preoperative CT scores, and 3-month E-scores as predictive factors for secondary treatment. Three-month E-scores showed higher sensitivity and specificity, and the odds ratio was 11.3 when the cut-off value was set at 10., Conclusion: The early identification of patients for whom ESS may fail is important and additional treatments need to be provided at the appropriate timing where needed. Patients with the following factors need to be carefully followed up: a young age, high preoperative CT score, and high early postoperative E-score., Competing Interests: Declaration of Competing Interest None., (Copyright © 2023. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
11. Impact of the lipase inhibitor orlistat on the human gut microbiota.
- Author
-
Uehira Y, Ueno H, Miyamoto J, Kimura I, Ishizawa Y, Iijima H, Muroga S, Fujita T, Sakai S, Samukawa Y, Tanaka Y, Murayama S, Sakoda H, and Nakazato M
- Subjects
- Humans, Orlistat pharmacology, Obesity, Body Weight, Fatty Acids, Lipase, Gastrointestinal Microbiome
- Abstract
Orlistat, an anti-obesity agent, inhibits the metabolism and absorption of dietary fat by inactivating pancreatic lipase in the gut. The effect of orlistat on the gut microbiota of Japanese individuals with obesity is unknown. This study aimed to explore the effects of orlistat on the gut microbiota and fatty acid metabolism of Japanese individuals with obesity. Fourteen subjects with visceral fat obesity (waist circumference ≥85 cm) took orlistat orally at a dose of 60 mg, 3 times a day for 8 weeks. Body weight; waist circumference; visceral fat area; levels of short-chain fatty acids, gut microbiota, fatty acid metabolites in the feces, and gastrointestinal hormones; and adverse events were evaluated. Body weight, waist circumference, and blood leptin concentrations were significantly lower after orlistat treatment (mean ± standard deviation, 77.8 ± 9.1 kg; 91.9 ± 8.7 cm; and 4546 ± 3211 pg/mL, respectively) compared with before treatment (79.4 ± 9.0 kg; 94.4 ± 8.0 cm; and 5881 ± 3526 pg/mL, respectively). Significant increases in fecal levels of fatty acid metabolites (10-hydroxy-cis-12-octadecenoic acid, 10-oxo-cis-12-octadecenoic acid, and 10-oxo-trans-11-octadecenoic acid) were detected. Meanwhile, no significant changes were found in abdominal computed tomography parameters, blood marker levels, or short-chain fatty acid levels in the feces. Gut microbiota analysis revealed that some study subjects had decreased abundance of Firmicutes, increased abundance of Bacteroidetes, and increased α-diversity indices (Chao1 and ACE) after 8 weeks of treatment. The levels of Lactobacillus genus and Lactobacillus gasseri were significantly higher after 8 weeks of treatment. None of the subjects discontinued treatment or experienced severe adverse events. This study suggested that orlistat might alter gut microbiota composition and affect the body through fatty acid metabolites produced by the modified gut bacteria., Competing Interests: Declaration of Competing Interest All investigators in this study declared Conflict of No Interest., (Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
12. A highly specific recurrent pleomorphic adenoma of the nasal septum.
- Author
-
Akiyama K, Karaki M, Samukawa Y, and Hoshikawa H
- Subjects
- Female, Humans, Aged, Aged, 80 and over, Nasal Septum diagnostic imaging, Nasal Septum surgery, Nasal Septum pathology, Nasal Cavity pathology, Adenoma, Pleomorphic diagnostic imaging, Adenoma, Pleomorphic surgery, Adenoma, Pleomorphic pathology, Nose Neoplasms diagnostic imaging, Nose Neoplasms surgery, Nose Neoplasms pathology, Nasal Obstruction etiology, Nasal Obstruction surgery
- Abstract
A 90-year-old woman presented with the sudden onset of visual loss. She previously underwent surgery to treat a right septal pleomorphic adenoma (PA) at 77 years old. She initially presented to our hospital with severe nasal obstruction at 83 years old. A large tumor occupied the bilateral nasal cavities and, thus, surgery was performed using midfacial degloving and an endoscopic endonasal combined approach. A 60×45×43 mm tumor was completely removed; however, a small area of the tumor capsule was damaged. Six years after surgery, PA recurred in the posterior midline portion of the nasal cavity. Imaging examinations revealed a 48×42×45 mm mass, which compressed the bilateral optic canal, thereby causing severe visual loss. The recurrent tumor was endoscopically removed, and vision recovered after surgery. The lack of malignant transformation was pathologically confirmed throughout this period. The present case had several highly specific features: she was very elderly, the tumor was very large, and visual dysfunction was caused by nasal PA. We described surgical procedures in detail and considered the specific findings of the present case. En bloc resection with a sufficient margin was considered to be important in the present case because recurrence may be caused by incomplete excision., Competing Interests: Conflict of Interest None., (Copyright © 2022. Published by Elsevier B.V.)
- Published
- 2023
- Full Text
- View/download PDF
13. The Utility of Glasgow Prognostic Score and Palliative Prognostic Index in Patients With Head and Neck Squamous Cell Carcinoma Under Palliative Care.
- Author
-
Kishino T, Mori T, Miyashita T, Ouchi Y, Samukawa Y, Fukumura T, Takahashi S, Monden N, Akisada N, Hayashi Y, Nakamura M, and Hoshikawa H
- Subjects
- Humans, Squamous Cell Carcinoma of Head and Neck therapy, Retrospective Studies, Prognosis, Palliative Care, Head and Neck Neoplasms therapy
- Abstract
Objectives: Palliative care patients with head and neck squamous cell carcinoma (HNSCC) often experience dysphagia and airway trouble; thus, each patient requires a specific palliative care plan based on their prognostication. However, no established specific prognostic tool performed on the day of starting end-of-life care is available for such patients. We assessed the accuracy of Glasgow prognostic score (GPS) and palliative prognostic index (PPI) and their combination to establish a specified prognostic tool for patients with HNSCC in end-of-life setting., Methods: A retrospective clinical chart review was undertaken on patients with HNSCC in end-of life setting who were decided in Kagawa University Hospital and National Hospital Organization Shikoku Cancer Center between April 2011 and March 2019. The patients were divided into 2 categories according to GPS (0-1 and 2) and PPI (groups A-B and C). These were combined into 4 categories (PPI group A-B and GPS score 0-1: good; PPI group A-B and GPS score 2: intermediate; PPI group C and GPS score 2: poor; and PPI group C and GPS score 0-1: others). The survival curves were compared for the former 3 categories., Results: The median survival of the scores 0-1 and 2 on GPS were 114 (72-148) and 39 (25-52) days, respectively ( P < .01). These of groups A-B and C on PPI were 79 (64-99) and 16 (9-29) days, respectively ( P < .01). The median survival of the good, intermediate, and poor categories was 127 (73-149), 64 (44-80), and 15 (9-27) days, respectively ( P < .01 among all categories)., Conclusions: In this study, the survival of terminally ill patients with HNSCC can be predicted by the GPS, PPI, and their combination with sufficient probability.
- Published
- 2023
- Full Text
- View/download PDF
14. Early postoperative endoscopic score can predict the long-term endoscopic outcomes in eosinophilic chronic rhinosinusitis (ECRS) patients.
- Author
-
Akiyama K, Samukawa Y, and Hoshikawa H
- Subjects
- Humans, Retrospective Studies, Endoscopy, Chronic Disease, Rhinitis surgery, Sinusitis surgery, Nasal Polyps surgery
- Abstract
Objective: Eosinophilic Chronic Rhinosinusitis (ECRS) is refractory and recurrent, requiring long-term follow-up after Endoscopic Sinus Surgery (ESS). Endoscopic evaluation is common during postoperative assessment, but how the findings vary over time in postoperative ECRS patients who were treated by the recent standardized management is unclear. We assessed the long-term change in postoperative endoscopic score in ECRS patients using a novel endoscopic scoring system (Escore)., Methods: This retrospective study included 80 ECRS patients who underwent full-house ESS and were followed for longer than 1-year. Endoscopic procedures were repeated at every follow-up visit and postoperative Escores were assessed from 3-months up to 5-years (median follow-up period was 3-years)., Results: The Escore did not significantly change from that at 3-months (3m-Escore). The Escore at the final observation point (f-Escore) among 80 patients was 9.2 ± 5.6 and there was no significant difference from the 3m-Escore (8.5 ± 4.1, p = 0.363). Twenty-one patients (21/80, 26.3%) were considered to have endoscopically uncontrolled ECRS at their final observation points and the 3m-Escore was identified as an independent predictive factor by multivariate logistic regression analysis. The 3m-Escore cut-off value that was able to predict endoscopically uncontrolled ECRS after long-term follow-up was ≥12., Conclusion: We demonstrated the long-term endoscopic outcomes after full-house ESS and continuous outpatient treatment. Early endoscopic findings (3m-Escore) were a potential predictive factor for the later endoscopic outcome, and a 3m-Escore of 12 or higher may be an indicator of the poor long-term prognosis of sinus mucosa., (Copyright © 2021 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier Editora Ltda. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
15. Olfactory cleft polyposis and respiratory epithelial adenomatoid hamartoma in eosinophilic chronic rhinosinusitis.
- Author
-
Akiyama K, Samukawa Y, and Hoshikawa H
- Subjects
- Diagnosis, Differential, Humans, Respiratory Mucosa pathology, Hamartoma diagnosis, Hamartoma pathology, Nasal Polyps pathology, Nose Neoplasms pathology, Sinusitis pathology
- Published
- 2020
- Full Text
- View/download PDF
16. 4-Hydroxyderricin and xanthoangelol isolated from Angelica keiskei prevent dexamethasone-induced muscle loss.
- Author
-
Yoshioka Y, Samukawa Y, Yamashita Y, and Ashida H
- Subjects
- Animals, Cell Line, Cell Survival drug effects, Chalcones antagonists & inhibitors, Chalcones isolation & purification, Isoflavones, Male, Mice, Mice, Inbred C57BL, Muscular Atrophy chemically induced, Phenols, Phosphorylation, Quality of Life, Angelica chemistry, Chalcone analogs & derivatives, Chalcone isolation & purification, Dexamethasone adverse effects, Muscles drug effects, Muscular Atrophy prevention & control, Plant Extracts pharmacology
- Abstract
Since a decrease in muscle mass leads to an increased risk of mortality, the prevention of muscle wasting contributes to maintaining the quality of life. Recently, we reported that glabridin, a prenylated flavonoid in licorice, prevents dexamethasone-induced muscle loss. In this study, we focused on the other prenylated chalcones 4-hydroxyderricin and xanthoangelol in Ashitaba (Angelica keiskei) and investigated their prevention effect on dexamethasone-induced muscle loss. It was found that 4-hydroxyderricin and xanthoangelol significantly prevented dexamethasone-induced protein degradation in C2C12 myotubes by suppressing the expression of ubiquitin ligases, Cbl-b and MuRF-1. These prenylated chalcones acted as the antagonists of the glucocorticoid receptor and inhibited the binding of dexamethasone to this receptor and its subsequent nuclear translocation. In addition, the chalcones suppressed the phosphorylation of p38 and FoxO3a as the upstream factors for ubiquitin ligases. Dexamethasone-induced protein degradation and upregulation of Cbl-b were attenuated by the knockdown of the glucocorticoid receptor but not by the knockdown of p38. In male C57BL/6J mice, the Ashitaba extract, containing 4-hydroxyderricin and xanthoangelol, suppressed dexamethasone-induced muscle mass wasting accompanied by a decrease in the expression of ubiquitin ligases by inhibiting the nuclear translocation of the glucocorticoid receptor and phosphorylation of FoxO3a. In conclusion, 4-hydroxyderricin and xanthoangelol are effective compounds to inhibit steroid-induced muscle loss.
- Published
- 2020
- Full Text
- View/download PDF
17. Short-term outcomes of olfaction in patients with eosinophilic chronic rhinosinusitis after endoscopic sinus surgery and an assessment of prognostic factors.
- Author
-
Akiyama K, Samukawa Y, and Hoshikawa H
- Subjects
- Adult, Aged, Chronic Disease, Female, Humans, Male, Middle Aged, Prognosis, Sex Characteristics, Smell, Endoscopy, Eosinophilia surgery, Olfaction Disorders surgery, Paranasal Sinuses surgery, Rhinitis surgery, Sinusitis surgery
- Abstract
Background: Olfactory dysfunction is one of the common symptoms of eosinophilic chronic rhinosinusitis (ECRS), for which endoscopic sinus surgery (ESS) is the standard treatment. Although the success rates of ESS for restoring olfaction in CRS have been reported, those for ECRS, as defined by new Japanese diagnostic criteria, remain unclear and the parameters affecting improvement rates have not yet been identified., Methods: Eighty-four patients with ECRS who underwent full-house ESS were retrospectively investigated. Olfactory function was examined using T&T recognition thresholds before and 3 months after surgery., Results: The total positive improvement rate in olfaction was 76.2% (64 of 84) and the mean T&T recognition threshold decreased significantly from 5.2 ± 1.1 to 3.0 ± 1.8 after surgery (p < 0.001). Some factors, including negative intravenous olfaction test, presence of olfactory cleft (OC) lesions, a history of sinus surgery, age ≥ 45 years, and being male, were more frequent in the olfaction refractory group. Furthermore, improvement of the T&T recognition threshold was significantly lower for factors of negative intravenous olfaction testing, the presence of OC lesions, and being male. Age and the proportion of blood eosinophils correlated with improvement., Conclusion: Herein we examined prognostic factors for olfactory outcomes in ECRS treated with ESS. The intravenous olfaction test, presence of OC lesions, sex differences, and age (the cut-off value was 45 years) were identified as independent prognostic factors for olfactory outcomes 3 months after surgery., (© 2019 ARS-AAOA, LLC.)
- Published
- 2020
- Full Text
- View/download PDF
18. Glabridin inhibits dexamethasone-induced muscle atrophy.
- Author
-
Yoshioka Y, Kubota Y, Samukawa Y, Yamashita Y, and Ashida H
- Subjects
- Animals, Cell Line, Dexamethasone metabolism, Dexamethasone pharmacology, Forkhead Box Protein O3 metabolism, Male, Mice, Mice, Inbred C57BL, Muscle, Skeletal cytology, Muscle, Skeletal drug effects, Muscle, Skeletal metabolism, Muscular Atrophy chemically induced, Receptors, Glucocorticoid metabolism, Signal Transduction drug effects, p38 Mitogen-Activated Protein Kinases metabolism, Dexamethasone antagonists & inhibitors, Isoflavones pharmacology, Muscular Atrophy prevention & control, Phenols pharmacology
- Abstract
Prevention of muscle wasting is known to contribute to improving the quality of life and extending a healthy life. Recently, we have reported that licorice flavonoid oil containing glabridin, which is a prenylated isoflavone, enhances muscle mass in mice. In this study, we investigated the prevention effect of glabridin on dexamethasone-induced muscle atrophy and clarified its mechanism in cultured myotubes and in muscle of mice. Treatment with glabridin to C2C12 myotubes inhibited dexamethasone-induced protein degradation through dexamethasone-induced expression of ubiquitin ligases, MuRF1 and Cbl-b, but not atrogin-1. Mechanistically, glabridin inhibited nuclear translocation of the glucocorticoid receptor. Glabridin directly bound to the glucocorticoid receptor, resulting in the inhibition of binding between dexamethasone and the receptor protein. Glabridin also inhibited dexamethasone-induced phosphorylation of p38 and FoxO3a, as the upstream for the induction of ubiquitin ligases in C2C12 myotubes. Moreover, the glabridin-induced inhibition of protein degradation was eliminated by knockdown of the glucocorticoid receptor, but not by p38 knockdown. These data indicated that the inhibitory mechanism of glabridin against dexamethasone-induced muscle atrophy was mainly mediated by the inhibition of binding between dexamethasone and the glucocorticoid receptor in myotubes. Oral administration of glabridin prevented dexamethasone-induced protein degradation in the tibialis anterior muscle of mice. It was confirmed that glabridin inhibited dexamethasone-induced nuclear translocation of the glucocorticoid receptor and phosphorylation of FoxO3a in the muscle of mice. These findings suggest that glabridin is an effective food ingredient for the prevention of glucocorticoid-induced skeletal muscle atrophy., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
19. A physiological concentration of luteolin induces phase II drug-metabolizing enzymes through the ERK1/2 signaling pathway in HepG2 cells.
- Author
-
Kitakaze T, Makiyama A, Samukawa Y, Jiang S, Yamashita Y, and Ashida H
- Subjects
- Aldehyde Dehydrogenase, Mitochondrial metabolism, Aldo-Keto Reductases metabolism, Diet, Enzyme Activation, Glutathione Transferase metabolism, Heme Oxygenase-1 metabolism, Hep G2 Cells, Humans, Luteolin administration & dosage, NAD(P)H Dehydrogenase (Quinone) metabolism, NF-E2-Related Factor 2 chemistry, NF-E2-Related Factor 2 metabolism, Phosphorylation, Ubiquitination, Enzymes metabolism, Luteolin metabolism, MAP Kinase Signaling System
- Abstract
The flavon luteolin has various health-promoting activities including cardiovascular protection, anti-inflammatory activity and anticancer activity. A serum concentration of about 100 nM luteolin is reached by dietary habit. However, little is known about the function of luteolin over its physiological concentration range. In this study, we investigated whether a physiological concentration of luteolin could activate nuclear factor-erythroid-2-related factor 2 (Nrf2)-mediated expression of phase II drug-metabolizing enzymes in human hepatoma HepG2 cells. Interestingly, less than 1 nM of luteolin could induce phase II drug-metabolizing enzymes, such as GSTs, HO-1, and NQO1. Both 1 and 100 nM luteolin increased expression and activity of ALDH2, which metabolized toxic acetaldehyde into nontoxic acetic acid. Luteolin increased nuclear accumulation of Nrf2 and enhanced the ARE-binding complex through increasing the stability of the Nrf2 protein. Luteolin increased phosphorylation of Nrf2 at Ser40, and MEK inhibitors (U0126 and PD98059) canceled luteolin-induced phosphorylation of Nrf2. Furthermore, luteolin increased modified Keap1. In conclusion, a physiological concentration of luteolin induces the expression of phase II drug-metabolizing enzymes by enhancement of Nrf2 nuclear accumulation through MEK1/2-ERK1/2-mediated phosphorylation of Nrf2, increasing Nrf2 stability and inducing a conformational change of Keap1., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
20. Impact of Preoperative Systemic Corticosteroids on the Histology and Diagnosis of Eosinophilic Chronic Rhinosinusitis.
- Author
-
Akiyama K, Makihara S, Uraguchi K, Samukawa Y, Oka A, and Hoshikawa H
- Subjects
- Adrenal Cortex Hormones administration & dosage, Adult, Aged, Biomarkers, Biopsy, Chronic Disease, Eosinophilia drug therapy, Eosinophils drug effects, Female, Humans, Leukocyte Count, Male, Middle Aged, Nasal Polyps diagnosis, Preoperative Care, Rhinitis surgery, Sinusitis surgery, Treatment Outcome, Adrenal Cortex Hormones therapeutic use, Eosinophilia pathology, Eosinophils pathology, Rhinitis diagnosis, Rhinitis drug therapy, Sinusitis diagnosis, Sinusitis drug therapy
- Abstract
Background: The histological changes corticosteroids induce in nasal polyps, and whether these changes have an impact on the diagnosis of eosinophilic chronic rhinosinusitis (ECRS), currently remain unclear., Objectives: A prospective controlled multicenter trial was conducted to evaluate the efficacy of the low-dose and short-term oral prednisolone (oPSL) treatment for tissue eosinophil infiltrations in ECRS., Methods: Subjects with ECRS diagnosed by previous biopsies received a low dose of oPSL for 3 days (PSL 3) or 7 days (PSL 7) before surgery. Changes in the tissue eosinophil count after these treatments were evaluated. Furthermore, the percent change of tissue eosinophil count from baseline and its impact on the diagnosis defined by the JESREC study were examined., Results: There were 23 and 21 subjects in the PSL 3 and PSL 7 groups, respectively. Polyp scores, clinical symptom scores, and the proportion of blood eosinophils significantly decreased after the treatment, and no significant differences were observed between the groups. The entire tissue eosinophil count tended to be slightly decreased in both groups without reaching a statistically significant value. The median percent change of tissue eo-sinophil count from baseline was 83.6%, and only the posttreatment proportion of blood eosinophil showed a mild correlation with it. Seven out of 44 nasal polyp specimens collected from the superficial part of the middle meatus showed < 70 eosinophils/high-power field; therefore, the false negative rate was 15.9%, but decreased to 11.4% when other parts were included in the histological evaluation., Conclusions: Low-dose and short-term oPSL did not appear to markedly affect the tissue eosinophil count in ECRS patients; however, the potential for misdiagnoses due to the effects of oPSL cannot be rejected. The diagnosis of ECRS prior to the administration of corticosteroids or tissue evaluations using multiple tissue parts is desirable., (© 2019 S. Karger AG, Basel.)
- Published
- 2019
- Full Text
- View/download PDF
21. Reduction of Excessive Visceral Fat and Safety with 52-Week Administration of Lipase Inhibitor Orlistat in Japanese: Long-Term Clinical Study.
- Author
-
Shirai K, Tanaka M, Fujita T, Fujii Y, Shimomasuda M, Sakai S, and Samukawa Y
- Subjects
- Adult, Anthropometry, Body Weight, Female, Humans, Japan, Longitudinal Studies, Male, Middle Aged, Anti-Obesity Agents therapeutic use, Intra-Abdominal Fat, Lactones therapeutic use, Obesity drug therapy, Orlistat therapeutic use
- Abstract
Introduction: Orlistat is an inhibitor of pancreatic lipase and is used as an anti-obesity drug in many countries. However, there are no data available regarding the effects of orlistat on visceral fat (VF) accumulation in Japanese individuals. Therefore, this study aimed to analyze the efficacy and safety of 52 weeks of orlistat administration in Japanese individuals., Methods: Orlistat 60 mg was administered orally three times daily for 52 weeks to Japanese participants with excessive VF accumulation and without dyslipidemia, diabetes mellitus, and hypertension (metabolic diseases). Participants were also counseled to improve their diet and to maintain exercise habits. We defined excessive VF accumulation as a waist circumference (WC) of ≥ 85 cm for males and ≥ 90 cm for females, which corresponds to a VF area of 100 cm
2 . Adverse reactions, clinical laboratory tests, VF, WC, body weight (BW), etc., were monitored throughout the study period., Results: VF, WC, and BW were significantly reduced at week 52 from baseline; the mean ± standard error rate of change was - 21.52% ± 1.89%, - 4.89% ± 0.45%, and - 5.36% ± 0.56%, respectively, and continued to reduce throughout the 52 weeks; these significantly reduced at whole term compared with baseline. Most adverse reactions were defecation-related symptoms such as oily spotting and flatus with discharge (flatus with small amounts of stool or oil) due to the pharmacologic effects of the lipase inhibitor. These symptoms were mostly mild, reversible, and recognizable by the participants; none were serious or severe. No participants discontinued by medical judgment about adverse reactions, and the drug could be administered continuously., Conclusion: VF, WC, and BW were reduced from week 4 to week 52, indicating the effect of long-term orlistat administration. Moreover, it was well tolerated with an acceptable safety profile. Long-term administration of orlistat may be efficacious in reducing VF accumulation with safety when used in combination with diet and exercise., Trial Registration: This study is registered with the Japan Pharmaceutical Information Center (identifier: JapicCTI-184004)., Funding: Funding for this study was provided by Taisho Pharmaceutical Co., Ltd.- Published
- 2019
- Full Text
- View/download PDF
22. Assessment of Simultaneous Surgery for Odontogenic Sinusitis: Endoscopic Sinus Surgery With Endoscopic Apicoectomy.
- Author
-
Akiyama K, Nakai Y, Samukawa Y, Miyake M, and Hoshikawa H
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Treatment Outcome, Video Recording, Apicoectomy methods, Endoscopy methods, Microsurgery methods, Paranasal Sinuses surgery, Sinusitis surgery
- Abstract
Odontogenic sinusitis (OS) is a disease commonly encountered by otolaryngologists and oral surgeons. There is currently no standard consensus for the management of the causative teeth of OS, and the therapeutic outcomes of endodontic surgery remain unclear. The authors herein report the outcomes of simultaneous surgery for OS, endoscopic sinus surgery (ESS) with endoscopic apicoectomy. Twenty-one OS patients who underwent ESS were included in the intent-to-treat population. Eleven patients who simultaneously underwent endoscopic apicoectomy were included as the study group, and another 10 patients who were subjected to the extraction of the causative teeth preceding or during surgery were included as the control group. The postoperative tooth course after surgery in the study group was assessed as the primary outcome by periodic radiographs. The postoperative sinus course was compared between the 2 groups as the secondary outcome. Seventeen teeth were subjected to endoscopic apicoectomy concurrently with ESS, and the treatment success rate for periapical lesions was 94.1% (16 out of 17 teeth), which was consistent with previously reported outcomes for endodontic microsurgery. Ten of 11 patients (90.9%) had good postoperative sinus courses, and the mean wound-healing period of the sinus mucosa was 6.9 ± 3.5 weeks. These results were not significantly different from those obtained for the control group (90% and 6.1 ± 3.2 weeks). This surgical procedure may contribute to the preservation of causative teeth without having an impact on the successful treatment of sinusitis. A comprehensive surgical approach by otolaryngologists and oral surgeons is desirable for the treatment of OS.
- Published
- 2019
- Full Text
- View/download PDF
23. Efficacy and Safety of Lipase Inhibitor Orlistat in Japanese with Excessive Visceral Fat Accumulation: 24-Week, Double-Blind, Randomized, Placebo-Controlled Study.
- Author
-
Shirai K, Fujita T, Tanaka M, Fujii Y, Shimomasuda M, Sakai S, and Samukawa Y
- Subjects
- Adult, Anthropometry, Body Mass Index, Body Weight drug effects, Combined Modality Therapy, Double-Blind Method, Female, Humans, Japan, Male, Middle Aged, Obesity therapy, Orlistat, Treatment Outcome, Anti-Obesity Agents therapeutic use, Exercise, Intra-Abdominal Fat pathology, Obesity drug therapy
- Abstract
Introduction: Orlistat is an inhibitor of pancreatic lipase and is used as an anti-obesity drug in many countries. However, there are no data available regarding the effects of orlistat on visceral fat accumulation in Japanese subjects. Therefore, this comparative, placebo-controlled, double-blind, randomized study aimed to evaluate the efficacy and safety of orlistat in Japanese participants with excessive visceral fat accumulation and without dyslipidemia, diabetes mellitus, and hypertension ("metabolic diseases")., Methods: The study population included Japanese participants with excessive visceral fat accumulation (waist circumference ≥ 85 cm in males and ≥ 90 cm in females, which corresponds to a visceral fat area of 100 cm
2 ) and without metabolic diseases. Following a 12-week observation term, participants were randomized to the orlistat 60 mg group (n = 100) or placebo group (n = 100). Both drugs were administered orally three times daily for 24 weeks. Participants were also counseled to improve their diet and to maintain exercise throughout the study. Visceral fat area, subcutaneous fat area, waist circumference, body weight, body mass index, adverse reactions, laboratory tests, and blood pressure were regularly assessed., Results: Visceral fat area, waist circumference, and body weight were significantly reduced in the orlistat group (mean ± standard error, - 13.50 ± 1.52%, - 2.51 ± 0.25%, and - 2.79 ± 0.30%, respectively) compared to the placebo group (- 5.45 ± 1.50%, - 1.55 ± 0.26%, and - 1.22 ± 0.28%, respectively) at the last assessment. The main adverse reactions were defecation-related symptoms including oily spotting and flatus with discharge, resulting from the pharmacological effects of orlistat. Most adverse reactions were mild, and none were serious or severe., Conclusion: Orlistat administration reduced visceral fat area, waist circumference, and body weight in Japanese participants with excessive visceral fat and without metabolic diseases. In addition, safety was confirmed with a tolerable profile. Orlistat may be useful to reduce excessive visceral fat accumulation when used in combination with diet and exercise., Trial Registration: Japan Pharmaceutical Information Center identifier, JapicCTI-184005., Funding: Taisho Pharmaceutical Co., Ltd.- Published
- 2019
- Full Text
- View/download PDF
24. Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment.
- Author
-
Samukawa Y, Haneda M, Seino Y, Sasaki T, Fukatsu A, Kubo Y, Sato Y, and Sakai S
- Subjects
- Adult, Aged, Asian People, Blood Glucose drug effects, Diabetes Complications blood, Diabetes Mellitus, Type 2 blood, Female, Glomerular Filtration Rate, Humans, Male, Middle Aged, Renal Insufficiency blood, Renal Insufficiency physiopathology, Sodium-Glucose Transporter 2 Inhibitors pharmacology, Sodium-Glucose Transporter 2 Inhibitors therapeutic use, Sorbitol adverse effects, Sorbitol pharmacokinetics, Sorbitol pharmacology, Sorbitol therapeutic use, Young Adult, Diabetes Complications physiopathology, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 drug therapy, Renal Insufficiency complications, Sodium-Glucose Transporter 2 Inhibitors adverse effects, Sodium-Glucose Transporter 2 Inhibitors pharmacokinetics, Sorbitol analogs & derivatives
- Abstract
This open-label, parallel-group, multicenter study aimed to assess the effects of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of luseogliflozin. A single 5-mg dose of luseogliflozin was administered to Japanese patients with type 2 diabetes mellitus in the following groups: G1, normal renal function; G2, mild renal impairment; G3a, mild to moderate impairment; G3b, moderate to severe impairment; G4, severe impairment, based on estimated glomerular filtration rate (eGFR; ≥90, 60-89, 45-59, 30-44, 15-29 mL/min/1.73 m
2 , respectively). While luseogliflozin pharmacokinetics were similar for patients across all renal function groups, the increase in plasma concentration was slightly slower and maximum concentration was slightly reduced in the lower eGFR groups compared with the other groups. However, luseogliflozin pharmacodynamics were affected by the severity of renal impairment. Urinary glucose excretion (UGE) increased in all groups relative to baseline levels, but the degree of UGE increase was smaller in the lower eGFR groups. Moreover, plasma glucose AUC changes from baseline tended to be smaller in the lower eGFR groups. No clear trends were observed between eGFR and incidence, type, or severity of adverse events. Thus, luseogliflozin administration should be carefully considered, as patients with renal impairment may show an insufficient response to treatment., (© 2018 The Authors. Clinical Pharmacology in Drug Development Published by Wiley Periodicals, Inc. on behalf of The American College of Clinical Pharmacology.)- Published
- 2018
- Full Text
- View/download PDF
25. Clinical effects of submucosal middle turbinectomy for eosinophilic chronic rhinosinusitis.
- Author
-
Akiyama K, Samukawa Y, Takahashi S, Ouchi Y, and Hoshikawa H
- Subjects
- Adult, Aged, Chronic Disease, Endoscopy, Female, Humans, Male, Middle Aged, Nasal Septum diagnostic imaging, Natural Orifice Endoscopic Surgery, Otorhinolaryngologic Surgical Procedures methods, Postoperative Complications diagnostic imaging, Prospective Studies, Tissue Adhesions diagnostic imaging, Tissue Adhesions epidemiology, Tomography, X-Ray Computed, Treatment Outcome, Turbinates diagnostic imaging, Eosinophilia surgery, Nasal Surgical Procedures methods, Postoperative Complications epidemiology, Rhinitis surgery, Sinusitis surgery, Turbinates surgery
- Abstract
Objective: The preservation or resection of the middle turbinate (MT) during endoscopic sinus surgery (ESS) currently remains a matter of debate. The present study aimed to investigate the effects of submucosal middle turbinectomy (SMT) in ESS for eosinophilic chronic rhinosinusitis (ECRS)., Methods: The study included 38 ECRS patients (63 sides) who had undergone full-house ESS with SMT and 20 ECRS patients (40 sides) without SMT as a control group. Post-operative middle turbinate lateralization (MTL), synechia formation, and the patency grade of the olfactory cleft (OC) were assessed as the primary outcomes 3 months after surgery. CT scans and the T&T test were performed on the SMT group 3 months after surgery and assessed as secondary outcomes., Results: MTL and synechia formation rates were slightly higher in the control group than in the SMT group (20% vs. 7.9%, p=0.072, 17.5% vs. 9.5%, p=0.235), although neither reached statistically significance. The mean patency score of OC was significantly better in the SMT group than in the control group (0.5±0.6 vs. 1.3±0.7, <0.001). CT findings and T&T test scores showed good improvements after SMT combined with ESS. No major adverse events occurred due to SMT., Conclusion: We demonstrated the potential advantages of SMT for ECRS patients. This method may avoid physiological functional loss through its preservation of the mucosa and structure of the MT., (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
26. Luseogliflozin, an SGLT2 Inhibitor, in Japanese Patients With Mild/Moderate Hepatic Impairment: A Pharmacokinetic Study.
- Author
-
Samukawa Y, Sata M, Furihata K, Ito T, Ueda N, Ochiai H, Sakai S, and Kumagai Y
- Subjects
- Adult, Aged, Area Under Curve, Female, Glucose analysis, Humans, Hypoglycemic Agents administration & dosage, Liver Diseases blood, Liver Diseases urine, Male, Middle Aged, Sodium-Glucose Transporter 2, Sodium-Glucose Transporter 2 Inhibitors, Sorbitol administration & dosage, Sorbitol pharmacokinetics, Hypoglycemic Agents pharmacokinetics, Liver Diseases metabolism, Sorbitol analogs & derivatives
- Abstract
This open-label, parallel-group study evaluated the effect of mild and moderate hepatic impairment on the pharmacokinetics of a single dose of luseogliflozin in Japanese subjects. Thirteen subjects with hepatic impairment (mild, n = 8; moderate, n = 5) and 6 healthy subjects received a single 5-mg dose of luseogliflozin. Serial blood sampling over 72 hours and 24-hour urine collection were done for pharmacokinetic analysis of luseogliflozin and its metabolites and to measure pharmacokinetic and pharmacodynamic parameters, respectively. Demographic characteristics were similar at baseline for both groups. Geometric mean ratios of maximum plasma concentration (C
max ) and area under the plasma concentration-time curve from time zero to infinity (AUCinf [90%CI]) of unchanged luseogliflozin were 1.02 (0.790-1.32) and 0.774 (0.580-1.03), respectively, on comparing patients with hepatic impairment with healthy subjects, and 0.939 (0.752-1.17) and 1.00 (0.780-1.28), respectively, in subjects with mild and moderate hepatic impairment. Although mean plasma concentrations of metabolites were slightly higher in patients with hepatic impairment versus healthy subjects, their time-course plasma concentrations were very low compared with those of unchanged luseogliflozin. Single-dose luseogliflozin 5 mg was well tolerated by study participants, indicating luseogliflozin dose adjustment is not necessary in patients with mild and moderate hepatic impairment., (© 2017 The Authors. Clinical Pharmacology in Drug Development Published by Wiley Periodicals, Inc. on behalf of The American College of Clinical Pharmacology.)- Published
- 2017
- Full Text
- View/download PDF
27. Metabolite profiling and enzyme reaction phenotyping of luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, in humans.
- Author
-
Miyata A, Hasegawa M, Hachiuma K, Mori H, Horiuchi N, Mizuno-Yasuhira A, Chino Y, Jingu S, Sakai S, Samukawa Y, Nakai Y, and Yamaguchi JI
- Subjects
- Cytochrome P-450 CYP3A, Cytochrome P-450 Enzyme System metabolism, Glucose, Glucuronosyltransferase metabolism, Humans, Hydroxylation, Kinetics, Metabolic Networks and Pathways, Microsomes, Liver metabolism, Oxidation-Reduction, Sorbitol metabolism, UDP-Glucuronosyltransferase 1A9, Sodium-Glucose Transporter 2 Inhibitors, Sorbitol analogs & derivatives
- Abstract
1. To understand the clearance mechanism of luseogliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, we investigated its human metabolite profile and metabolic enzymes responsible for the primary metabolic pathways in human using reaction phenotyping. 2. Sixteen metabolites of luseogliflozin were found in human plasma and/or urine and their structural information indicated that the drug was metabolized via multiple metabolic pathways. The primary metabolic pathways involve (1) O-deethylation to form M2 and subsequent glucuronidation to form M12, (2) ω-hydroxylation at ethoxy group to form M3 followed by oxidation to form the corresponding carboxylic acid metabolite (M17) and (3) direct glucuronidation to form M8. 3. The reaction phenotyping studies indicated that the formation of M2 was mainly mediated by cytochrome P450 (CYP) 3A4/5, and subsequently M12 formation was catalyzed by UGT1A1, UGT1A8 and UGT1A9. The formation of M3 was mediated by CYP4A11, CYP4F2 and CYP4F3B, and the further oxidation of M3 to M17 was mediated by alcohol dehydrogenase and aldehyde dehydrogenase. The formation of M8 was catalyzed by UGT1A1. 4. These results demonstrate that luseogliflozin is metabolized through multiple pathways, including CYP-mediated oxidation and glucuronidation, in human.
- Published
- 2017
- Full Text
- View/download PDF
28. Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of Luseogliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Japanese Patients with Type 2 Diabetes Mellitus.
- Author
-
Samukawa Y, Mutoh M, Chen S, and Mizui N
- Subjects
- Adult, Aged, Asian People, Diabetes Mellitus, Type 2 blood, Diabetes Mellitus, Type 2 metabolism, Female, Glucose metabolism, Humans, Hypoglycemic Agents blood, Kidney Glomerulus metabolism, Kidney Tubules, Proximal metabolism, Male, Middle Aged, Sodium-Glucose Transporter 2 metabolism, Sodium-Glucose Transporter 2 Inhibitors, Sorbitol blood, Sorbitol pharmacokinetics, Sorbitol pharmacology, Hypoglycemic Agents pharmacokinetics, Hypoglycemic Agents pharmacology, Models, Biological, Sorbitol analogs & derivatives
- Abstract
Luseogliflozin is a selective sodium glucose co-transporter 2 (SGLT2) inhibitor that reduces hyperglycemia in type 2 diabetes mellitus (T2DM) by promoting urinary glucose excretion (UGE). A clinical pharmacology study conducted in Japanese patients with T2DM confirmed dose-dependency of UGE with once-daily administration of luseogliflozin; however, the reason for sustained UGE after plasma luseogliflozin decreased was unclear. To elucidate the effect of inhibition rate constants, K
on and Koff , and to explain the sustained UGE, a pharmacokinetic-pharmacodynamic (PK-PD) model was built based on the mechanisms of glucose filtration in the glomerulus and reabsorption in the renal proximal tubule of kidney as well as the kinetics of competitive inhibition of SGLT1/2 and inhibition rate constants of SGLT2, by using UGE and plasma glucose levels and luseogliflozin concentrations. This acquired population PK-PD model adequately described the sustained UGE and the estimated population means of the inhibition constant for SGLT2 (Ki2 ) and inhibition-rate constants for SGLT2 (Kon and Koff ) were 0.31- and 3.6-fold lower or higher than the in vitro values. Because the dissociation half-time of luseogliflozin from SGLT2 calculated from Koff , 6.81 h, was consistent with the value in vitro, we considered that the sustained UGE could be explained by the long dissociation half-time. Moreover, by calculating the SGLT2 inhibition ratio using the model, we discuss other properties of the UGE time course after luseogliflozin administration.- Published
- 2017
- Full Text
- View/download PDF
29. Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study.
- Author
-
Samukawa Y, Omiya H, Watase H, Nozaki K, Sakai S, and Nishimura R
- Subjects
- Aged, Blood Glucose drug effects, Cross-Over Studies, Double-Blind Method, Female, Humans, Hyperglycemia drug therapy, Hypoglycemic Agents therapeutic use, Japan, Male, Middle Aged, Postprandial Period drug effects, Sorbitol administration & dosage, Sorbitol adverse effects, Sorbitol therapeutic use, Diabetes Mellitus, Type 2 drug therapy, Sorbitol analogs & derivatives
- Abstract
Introduction: In our previous study investigating effects of luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, on 24-h glycemic variability by continuous glucose monitoring (CGM), luseogliflozin elicited parallel downward shifts in fasting and postprandial glucose levels. However, further review of individual patients' data revealed that postprandial hyperglycemia was not reduced in some patients, while preprandial glucose was ameliorated in most patients. Therefore, we divided patients into two groups according to their postprandial glucose responses and conducted a post hoc subanalyses to elucidate which factors contributed to the differential effects of luseogliflozin., Methods: Thirty-four Japanese type 2 diabetic patients in our previous randomized, double-blind, placebo-controlled, crossover study with 7-day luseogliflozin administration were divided into postprandial glucose responders (PGR, n = 23, ameliorated peak glucose) and postprandial glucose non-responders (PGNR; n = 11, non-ameliorated peak glucose). Baseline characteristics, variations in CGM-measured 24-h glucose levels, and other pharmacodynamic variabilities were compared., Results: Baseline characteristics did not differ significantly between groups. Placebo-subtracted peak glucose was significantly lowered in PGR and significantly increased in PGNR (-43.8 and 17.9 mg/dL; both p < 0.05). Luseogliflozin significantly lowered "lowest glucose" (defined as the lowest level measured throughout a 24-h period) similarly in PGR and PGNR (-19.2 and -24.0 mg/dL; both p < 0.05), significantly reduced the mean amplitude of glucose excursions in PGR (-15.50 mg/dL; p < 0.05), and increased the area under the curve for plasma glucagon over 24 h in PGNR (median difference vs. placebo: 240 pg/mL h; p < 0.05). Luseogliflozin increased urinary glucose excretion (UGE) and decreased serum insulin by similar magnitudes in both groups., Conclusions: Luseogliflozin diminished glucose fluctuations in most patients by lowering peak glucose to a greater extent than lowest glucose. Luseogliflozin may also lower lowest glucose in patients whose peak glucose was not ameliorated despite increasing UGE. The glucagon increase in PGNR might explain its hypoglycemic effect on postprandial glucose., Funding: Taisho Pharmaceutical Co., Ltd, Tokyo, Japan., Trial Registration: JapicCTI-142548.
- Published
- 2016
- Full Text
- View/download PDF
30. Preference evaluation and perceived sensory comparison of fluticasone furoate and mometasone furoate intranasal sprays in allergic rhinitis.
- Author
-
Yonezaki M, Akiyama K, Karaki M, Goto R, Inamoto R, Samukawa Y, Kobayashi R, Kobayashi E, and Hoshikawa H
- Subjects
- Administration, Intranasal, Adult, Aged, Cross-Over Studies, Female, Humans, Male, Middle Aged, Nasal Sprays, Sex Factors, Sneezing, Surveys and Questionnaires, Taste, Androstadienes therapeutic use, Anti-Allergic Agents therapeutic use, Mometasone Furoate therapeutic use, Patient Preference, Rhinitis, Allergic, Seasonal drug therapy
- Abstract
Objective: Intranasal corticosteroid sprays (INCSs) are commonly used for therapy of allergic rhinitis (AR). Adherence to regular use of INCSs is influenced by patient perception and preferences of products. The study objective was to compare perceived sensory attributes of fluticasone furoate nasal spray (FFNS) and mometasone furoate nasal spray (MFNS) in AR patients., Methods: In a multicenter, randomized, crossover, prospective study, 40 seasonal AR patients were administered both FFNS and MFNS for 2 weeks each in a crossover fashion, for a total of 4 weeks. Patients completed questionnaires for each product regarding perceived sensory attributes at the end of each two-week period of product administration., Results: FFNS was significantly preferred over MFNS. Significantly, fewer subjects perceived a bitter taste (p=0.01), medication running down their throat (p=0.033), and medication running out of their nose (p=0.002) with FFNS. MFNS was more frequently reported to induce nasal irritation (p=0.012), sneezing (p=0.017), and rhinorrhea (p=0.007) compared to FFNS. Interestingly, these findings were markedly observed in females. Medicine dripping out of the nose and nasal shooting were the most common problems reported for MFNS with a higher proportion of subjects who felt moderate-to-severe discomfort. Overall, 52.5% of patients expressed a preference for FFNS compared with 22.5% for MFNS., Conclusion: Several perceived sensory attributes of FFNS were rated significantly superior to MFNS. FFNS may contribute to enhanced treatment outcomes in AR patients due to improved treatment adherence., (Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
31. Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials.
- Author
-
Sakai S, Kaku K, Seino Y, Inagaki N, Haneda M, Sasaki T, Fukatsu A, Kakiuchi H, and Samukawa Y
- Subjects
- Body Mass Index, Humans, Japan, Sorbitol administration & dosage, Sorbitol adverse effects, Sorbitol therapeutic use, Diabetes Mellitus, Type 2 drug therapy, Hypoglycemic Agents administration & dosage, Hypoglycemic Agents adverse effects, Hypoglycemic Agents therapeutic use, Sorbitol analogs & derivatives
- Abstract
Purpose: Luseogliflozin, a sodium-glucose cotransporter-2 inhibitor, may be beneficial in obese diabetic patients based on its potential to decrease blood glucose and body weight, but there is limited proof. This analysis aimed to investigate the efficacy and safety of luseogliflozin in patients with varying levels of obesity., Methods: A pooled analysis of four 52-week Phase III trials of luseogliflozin 2.5 mg daily (or up to 5 mg daily) in Japanese patients with type 2 diabetes mellitus stratified according to baseline body mass index (BMI) was conducted. Efficacy end points included changes in glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG), and body weight., Findings: In total, 1031 patients were included and stratified into 5 BMI (kg/m(2)) groups: low-to-medium (<22.5, n = 222); medium (≥22.5 to <25, n = 270); high-level 1 (≥25 to <27.5, n = 262); high-level 2 (≥27.5 to <30, n = 142); and very-high (≥30, n = 135). HbA1c decreased significantly compared with baseline until week 52 in all groups, and a similar trend was observed with FPG and body weight. The reduction in glycemic parameters tended to be slightly smaller in patients with BMI <22.5 kg/m(2), and the reduction in body weight tended to be greater in patients with higher BMI, especially those with BMI ≥30 kg/m(2). Levels of fasting insulin, C-peptide immunoreactivity, triglyceride, blood pressure, aspartate aminotransferase, alanine aminotransferase, and uric acid decreased significantly at week 52 in all groups (except for aspartate aminotransferase in patients with BMI <22.5 kg/m(2)). Levels of these parameters tended to be higher at baseline and these enhanced levels resulted in a greater decrease in patients with higher BMI. In safety, the incidence of adverse events was similar between groups, and most of them were mild in severity., Implications: HbA1c and body weight decreased significantly in all groups. Decrease in glycemic parameters tended to be smaller in patients with BMI <22.5 kg/m(2), while that of body weight was larger in patients with higher BMI. Furthermore, luseogliflozin was especially beneficial in patients with higher BMI in terms of metabolic abnormalities, including insulin secretion and hypertension. Luseogliflozin exhibited a favorable and similar safety profile over 52 weeks in all groups. This agent can be an effective and well-tolerated therapeutic option in patients with a wide range of BMI levels, and it may be more beneficial in patients with higher BMI., (Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
32. Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus.
- Author
-
Jinnouchi H, Nozaki K, Watase H, Omiya H, Sakai S, and Samukawa Y
- Subjects
- Adult, Aged, Asian People, Cross-Over Studies, Double-Blind Method, Female, Glycated Hemoglobin drug effects, Humans, Hypoglycemic Agents pharmacology, Japan, Male, Middle Aged, Renal Insufficiency physiopathology, Sodium-Glucose Transporter 2, Sodium-Glucose Transporter 2 Inhibitors, Sorbitol pharmacology, Sorbitol therapeutic use, Blood Glucose drug effects, Diabetes Mellitus, Type 2 drug therapy, Diabetes Mellitus, Type 2 epidemiology, Hypoglycemic Agents therapeutic use, Renal Insufficiency epidemiology, Sorbitol analogs & derivatives
- Abstract
Introduction: We investigated the impact of reduced renal function on 24-h glucose variability in Japanese patients with type 2 diabetes mellitus (T2DM) treated with luseogliflozin., Methods: In this double-blind, placebo-controlled, crossover study, 37 Japanese patients with T2DM [glycated hemoglobin (HbA1c) 7.0-10.0%] and estimated glomerular filtration rate (eGFR) ≥45 mL/min/1.73 m(2) were randomized into two groups in which patients first received luseogliflozin then placebo, or vice versa, for 7 days each. Twenty-four-hour glucose variability was measured on day 7 in each period and was compared among patients divided into three groups according to their baseline eGFR (mL/min/1.73 m(2)): normal (≥90; n = 13; normal group), normal-to-mildly reduced renal function (≥75 to <90; n = 12; normal-mild group), and mild-to-moderately reduced renal function (<75; n = 9; mild-moderate group)., Results: The mean [95% confidence interval (CI)] placebo-subtracted 24-h cumulative urinary glucose excretion (g) was 82.1 (72.7, 91.5), 82.5 (73.4, 91.5), and 62.2 (51.2, 73.3); the placebo-subtracted 24-h mean glucose concentration (mg/dL) was -24.39 (-32.53, -16.26), -28.28 (-39.35, -17.22), and -11.53 (-23.93, 0.86); and the placebo-subtracted peak postprandial glucose (mg/dL) was -26.9 (-46.9, -6.9), -38.1 (-59.6, -16.6), and 1.5 (-25.5, 28.4) in the normal, normal-mild, and mild-moderate groups, respectively. The mean lowest glucose concentrations (placebo vs. luseogliflozin, mg/dL) decreased to similar levels in the normal (115.4 vs. 93.4), normal-mild (121.0 vs. 97.9), and mild-moderate (104.0 vs. 91.1) groups., Conclusion: This post hoc subanalysis revealed that although mild-to-moderately reduced renal function attenuated the glucose-lowering effects of luseogliflozin on peak postprandial glucose, it did not attenuate the effects of luseogliflozin on fasting glucose. These findings may explain the smaller increase in urinary glucose excretion in these patients relative to patients with normal renal function or normal-to-moderately reduced renal function. Further studies may be needed to examine these findings in large populations of patients with T2DM and reduced renal function., Trial Registration: JapicCTI-142548., Funding: Taisho Pharmaceutical Co., Ltd.
- Published
- 2016
- Full Text
- View/download PDF
33. Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
- Author
-
Haneda M, Seino Y, Inagaki N, Kaku K, Sasaki T, Fukatsu A, Kakiuchi H, Sato Y, Sakai S, and Samukawa Y
- Subjects
- Adult, Aged, Blood Glucose analysis, Body Weight, Diabetes Mellitus, Type 2 blood, Diabetes Mellitus, Type 2 complications, Double-Blind Method, Drug Administration Schedule, Female, Glomerular Filtration Rate, Glycated Hemoglobin metabolism, Humans, Hypoglycemic Agents adverse effects, Japan, Male, Middle Aged, Renal Insufficiency complications, Sodium-Glucose Transport Proteins antagonists & inhibitors, Sorbitol adverse effects, Sorbitol therapeutic use, Treatment Outcome, Diabetes Mellitus, Type 2 drug therapy, Hypoglycemic Agents therapeutic use, Renal Insufficiency physiopathology, Sorbitol analogs & derivatives
- Abstract
Purpose: To evaluate the influence of renal function on the efficacy and safety of the sodium glucose cotransporter 2 inhibitor luseogliflozin (TS-071) in Japanese patients with type 2 diabetes mellitus (T2DM)., Methods: Study 1 was a 52-week, Phase III study to evaluate the efficacy and safety of 2.5 mg/d luseogliflozin (or increased to 5 mg/d) in patients with T2DM with moderate renal impairment. During the initial 24 weeks, efficacy and safety of luseogliflozin were compared with placebo. Study 2 was a pooled analysis of four 52-week, Phase III studies of luseogliflozin, including Study 1, to evaluate the efficacy and safety of luseogliflozin in patients with various degrees of renal function. Patients were stratified into 3 groups by baseline estimated glomerular filtration rate (eGFR): normal renal function (≥90 mL/min/1.73 m(2)), mild impairment (≥60 to <90 mL/min/1.73 m(2)), and moderate impairment (≥30 to <60 mL/min/1.73 m(2)). Patients with moderate impairment were further divided into those with mild-moderate (≥45 to <60 mL/min/1.73 m(2)) and moderate-severe (≥30 to <45 mL/min/1.73 m(2)). In both studies, efficacy end points included changes in glycated hemoglobin (HbA1c) level, fasting plasma glucose (FPG) level, and body weight. The safety end points included adverse events (AEs) and laboratory parameters., Findings: In Study 1, HbA1c, FPG, and body weight significantly decreased at Week 24 in patients treated with luseogliflozin compared with patients treated with placebo, with the decrease in these parameters also observed with luseogliflozin at Week 52. The incidence of AEs was similar between groups. In Study 2, 1030 patients were included (normal, 275; mildly impaired, 598; and moderately impaired, 157). At Week 52, HbA1c, FPG, and body weight were significantly decreased from baseline in all groups. In between-group comparisons, the decreases in HbA1c and body weight were significantly smaller in patients with moderate impairment than in those with normal function; however, the HbA1c-lowering efficacy was reduced by nearly half, whereas the efficacy of body weight lowering was not so much diminished in the moderate impairment group. Furthermore, a scatter plot showed that changes in HbA1c were more influenced by baseline HbA1c than by baseline eGFR. The incidence of AEs during 52 weeks was similar among all groups, with the majority being mild., Implications: Luseogliflozin improved glycemic control and reduced body weight in all eGFR groups, and its efficacy on HbA1c lowering was reduced in those with moderate renal impairment. Luseogliflozin was well tolerated and safe, with no significant safety issues identified, regardless of baseline eGFR. The study is registered with Clinical Trials Information/JapicCTI of the Japan Pharmaceutical Information Center, and the study registry identification numbers are JapicCTI-111507, JapicCTI-111508, JapicCTI-111509, and JapicCTI-111543., (Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
34. Corrigendum.
- Author
-
Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, and Samukawa Y
- Published
- 2015
- Full Text
- View/download PDF
35. Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects.
- Author
-
Kumagai Y, Hasunuma T, Sakai S, Ochiai H, and Samukawa Y
- Subjects
- Adult, Cross-Over Studies, Double-Blind Method, Electrocardiography, Female, Humans, Male, Sodium-Glucose Transporter 2, Sorbitol adverse effects, Sorbitol pharmacokinetics, Sorbitol pharmacology, Young Adult, Heart Rate drug effects, Sodium-Glucose Transporter 2 Inhibitors, Sorbitol analogs & derivatives
- Abstract
Luseogliflozin is a selective sodium glucose co-transporter 2 (SGLT2) inhibitor. To evaluate the cardiac safety of luseogliflozin, a thorough QT/QTc study was conducted in healthy Japanese subjects. The effects of moxifloxacin on QT prolongation in Japanese subjects were also evaluated. In this double-blind, placebo- and open-label positive-controlled, 4-way crossover study, 28 male and 28 female subjects received a single dose of luseogliflozin 5 mg (therapeutic dose), luseogliflozin 20 mg (supratherapeutic dose), placebo, and moxifloxacin 400 mg. Serial triplicate digital 12-lead electrocardiograms (ECGs) were recorded before and after dosing, and results were analyzed using the Fridericia correction (QTcF) method. Serial blood sampling was performed for pharmacokinetic analyses of luseogliflozin and moxifloxacin to analyze the relationship between QTcF interval and plasma concentration. The upper limits of the two-sided 90% confidence intervals (CIs) for baseline and placebo-adjusted QTcF intervals (ΔΔQTcF) in the 5 mg and 20 mg luseogliflozin groups were less than 10 ms at all time points. No correlation between plasma luseogliflozin concentrations and ΔΔQTcF was observed. In the moxifloxacin group, the lower limits of the two-sided 90% CIs for ΔΔQTcF were greater than 5 ms at all time points. A positive relationship was observed between plasma moxifloxacin concentration and change in ΔΔQTcF. Luseogliflozin was well tolerated at both dose levels. The majority of adverse events were mild in severity, and no serious or life-threatening adverse events occurred. Neither therapeutic (5 mg) nor supratherapeutic (20 mg) doses of luseogliflozin affected QT prolongation in healthy Japanese subjects.
- Published
- 2015
- Full Text
- View/download PDF
36. Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus.
- Author
-
Seino Y, Inagaki N, Haneda M, Kaku K, Sasaki T, Fukatsu A, Ubukata M, Sakai S, and Samukawa Y
- Abstract
Introduction: Two studies were carried out to investigate the efficacy and safety of luseogliflozin added to existing oral antidiabetic drugs (OADs) in Japanese type 2 diabetic patients inadequately controlled with OAD monotherapy., Materials and Methods: In the trial involving add-on to sulfonylureas (study 03-1), patients were randomly assigned to receive luseogliflozin 2.5 mg or a placebo for a 24-week double-blind period, followed by a 28-week open-label period. In the open-label trial involving add-on to other OADs; that is, biguanides, dipeptidyl peptidase-4 inhibitors, thiazolidinediones, glinides and α-glucosidase inhibitors (study 03-2), patients received luseogliflozin for 52 weeks., Results: In study 03-1, luseogliflozin significantly decreased glycated hemoglobin at the end of the 24-week double-blind period compared with the placebo (-0.88%, P < 0.001), and glycated hemoglobin reduction from baseline at week 52 was -0.63%. In study 03-2, luseogliflozin added to other OADs significantly decreased glycated hemoglobin from baseline at week 52 (-0.52 to -0.68%, P < 0.001 for all OADs). Bodyweight reduction was observed in all add-on therapies, even with agents associated with weight gain, such as sulfonylureas and thiazolidinediones. Most adverse events were mild in severity. When added to a sulfonylurea, incidences of hypoglycemia during the double-blind period were 8.7% and 4.2% for luseogliflozin and placebo, respectively, but no major hypoglycemic episodes occurred. The frequency and incidences of adverse events of special interest for sodium glucose cotransporter 2 inhibitors and adverse events associated with combined OADs were acceptable., Conclusions: Add-on therapies of luseogliflozin to existing OADs improved glycemic control, reduced bodyweight and were well tolerated in Japanese type 2 diabetic patients. These trials were registered with the Japan Pharmaceutical Information Center (add on to sulfonylurea: JapicCTI-111507; add on to other OADs: JapicCTI-111508).
- Published
- 2015
- Full Text
- View/download PDF
37. Prognostic value comparison between (18)F-FLT PET/CT and (18)F-FDG PET/CT volume-based metabolic parameters in patients with head and neck cancer.
- Author
-
Hoshikawa H, Mori T, Yamamoto Y, Kishino T, Fukumura T, Samukawa Y, Mori N, and Nishiyama Y
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell pathology, Female, Head and Neck Neoplasms pathology, Humans, Male, Middle Aged, Multimodal Imaging, Predictive Value of Tests, Tumor Burden, Carcinoma, Squamous Cell diagnostic imaging, Dideoxynucleosides, Fluorodeoxyglucose F18, Head and Neck Neoplasms diagnostic imaging, Positron-Emission Tomography, Radiopharmaceuticals, Tomography, X-Ray Computed
- Abstract
Purpose: The present study compared the potential of pretreatment 3'-deoxy-3'-[F]-fluorothymidine (F-FLT) uptake parameters and those of F-FDG to predict the clinical outcome of head and neck squamous cell carcinoma treated with chemoradiotherapy., Methods: A total 53 patients undergoing pretreatment F-FLT PET/CT and F-FDG PET/CT from May 2006 to April 2013 were evaluated. The SUVmax, metabolic tumor volume (MTV), total lesion glycolysis, and total lesion proliferation (TLP) were determined semiquantitatively. Associations between clinical factors and PET/CT parameters and prognostic value were analyzed., Results: In univariate analyses, F-FLT SUVmax, MTV, TLP, F-FDG MTV, and total lesion glycolysis correlated with locoregional control (P = 0.02, P = 0.0007, P = 0.0001, P = 0.007, and P = 0.013, respectively). Clinical T stage, F-FLT SUVmax, MTV, TLP, and F-FDG SUVmax correlated with overall survival (P = 0.012, P = 0.0057, P = 0.0018, P = 0.0012, and P = 0.047, respectively). On multivariate analyses, F-FLT TLP was an independent factor for locoregional control (P = 0.002; hazards ratio [HR], 5.13; 95% confidence interval [CI], 1.81-14.54), as were F-FLT SUVmax and MTV for overall survival (P = 0.021; HR, 3.47; 95% CI, 1.2-10.01 and P = 0.029; HR, 3.17; 95% CI, 1.12-8.95)., Conclusions: Pretreatment F-FLT PET/CT volume-based metabolic parameters are superior prognostic predictors to those of F-FDG PET/CT. F-FLT SUVmax and MTV can provide important prognostic information for patients with head and neck squamous cell carcinomas administered with chemoradiotherapy.
- Published
- 2015
- Full Text
- View/download PDF
38. Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males.
- Author
-
Sasaki T, Seino Y, Fukatsu A, Ubukata M, Sakai S, and Samukawa Y
- Subjects
- 1-Deoxynojirimycin administration & dosage, 1-Deoxynojirimycin analogs & derivatives, Adult, Area Under Curve, Cross-Over Studies, Female, Humans, Japan, Male, Metformin administration & dosage, Middle Aged, Pioglitazone, Pyrazines administration & dosage, Sitagliptin Phosphate administration & dosage, Sorbitol administration & dosage, Sulfonylurea Compounds administration & dosage, Thiazolidinediones administration & dosage, Triazoles administration & dosage, Antihypertensive Agents administration & dosage, Hypoglycemic Agents administration & dosage, Sorbitol analogs & derivatives
- Abstract
Introduction: We investigated the possibilities of drug-drug interactions between luseogliflozin, a sodium-glucose co-transporter-2 inhibitor, and oral antidiabetic drugs (OADs) in healthy Japanese males., Methods: We conducted six independent studies to investigate potential drug-drug interactions between 5 mg luseogliflozin and the following OADs usually used in Japan: 1 mg glimepiride, 250 mg metformin, 30 mg pioglitazone, 50 mg sitagliptin, 50 mg miglitol, or 0.6 mg voglibose (0.2 mg before each meal). Twelve subjects were enrolled in each study. The glimepiride, metformin, sitagliptin, and miglitol studies were randomized, open-label, single-dose, three-way crossover studies. The pioglitazone and voglibose studies were open-label studies, where a single dose of luseogliflozin was added to multiple doses of pioglitazone or voglibose. The endpoints were the area under the curve from 0 to 24 h (AUC0-24 h) or to infinity (AUCinf) and the maximum concentration (Cmax) of each drug administered alone or in combination., Results: The 90% confidence intervals (CIs) of the geometric mean ratio (GMR) for Cmax of luseogliflozin in the pioglitazone and miglitol studies were beyond the reference range for bioequivalence (0.80-1.25) (miglitol: 0.851 [0.761, 0.952]; pioglitazone: 1.16 [1.04, 1.30]). However, the 90% CIs for AUC0-24 h were within the reference range. The 90% CIs of the GMRs for Cmax and AUC0-24 h of pioglitazone were beyond the reference range (Cmax 0.884 [0.746, 1.05]; AUC0-24 h 0.896 [0.774, 1.04]), but the 90% CIs for the active metabolites of pioglitazone were within the reference range. For the other combinations tested, the 90% CIs and GMRs for luseogliflozin and the individual OADs were within the reference range., Conclusion: No clinically meaningful interactions were observed between luseogliflozin and six commonly used OADs in Japan, although there were some changes in the pharmacokinetics of pioglitazone co-administered with luseogliflozin and for luseogliflozin co-administered with miglitol or pioglitazone., Funding: Taisho Pharmaceutical Co., Ltd.
- Published
- 2015
- Full Text
- View/download PDF
39. Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial.
- Author
-
Sasaki T, Seino Y, Fukatsu A, Ubukata M, Sakai S, and Samukawa Y
- Subjects
- Adult, Aged, Asian People, Blood Glucose, Dose-Response Relationship, Drug, Female, Humans, Japan, Male, Middle Aged, Single-Blind Method, Sodium-Glucose Transporter 2 Inhibitors, Sorbitol pharmacokinetics, Sorbitol pharmacology, Sorbitol therapeutic use, Diabetes Mellitus, Type 2 drug therapy, Hypoglycemic Agents therapeutic use, Sorbitol analogs & derivatives
- Abstract
Introduction: Luseogliflozin, a potent, selective sodium glucose cotransporter 2 inhibitor, promotes urinary glucose excretion (UGE) and reduces plasma glucose concentrations. Luseogliflozin was approved for use in Japan after favorable pharmacokinetic, pharmacodynamic, and safety profiles were reported in healthy Japanese subjects and patients with type 2 diabetes mellitus (T2DM) in clinical development studies. We aimed to investigate the pharmacokinetics, pharmacodynamics, and safety of multiple doses of luseogliflozin administered once daily for 7 days in Japanese patients with T2DM., Methods: We conducted a randomized, placebo-controlled, single-blind, parallel-group, clinical pharmacology study at the P-One Clinic, Keikokai Medical Corporation (Tokyo, Japan) between August 2009 and November 2009. Forty Japanese patients with T2DM were randomly assigned to receive once-daily 0.5, 1, 2.5 or 5 mg luseogliflozin or placebo for 7 days. We assessed the pharmacokinetics, pharmacodynamics (including changes in UGE and plasma glucose concentrations), and safety of luseogliflozin., Results: The plasma concentrations of luseogliflozin and its active metabolite, M2, were dose proportional, without accumulation. 24-h UGE was greater in all luseogliflozin groups versus placebo. Least-squares mean differences in 24-h UGE on Day 7 increased dose dependently in the luseogliflozin groups, with values of 49.2, 66.5, 89.4, and 101 g/day at 0.5, 1, 2.5, and 5 mg, respectively. On Day 7, the areas under the concentration-time curves for post-meal plasma glucose and the mean plasma glucose for 0-16 h were significantly lower in all luseogliflozin groups versus placebo. Seven patients had mild adverse events (AEs); all were resolved. No AEs led to study discontinuation., Conclusion: Once-daily administration of luseogliflozin for 7 days increased 24-h UGE in a dose-dependent manner, reduced plasma glucose concentrations, and was well tolerated in Japanese patients with T2DM. The pharmacokinetic and pharmacodynamic profile of luseogliflozin observed in this study supports its once-daily dosing regimen., Funding: Taisho Pharmaceutical Co., Ltd.
- Published
- 2015
- Full Text
- View/download PDF
40. Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
- Author
-
Seino Y, Kaku K, Inagaki N, Haneda M, Sasaki T, Fukatsu A, Ubukata M, Sakai S, and Samukawa Y
- Subjects
- Aged, Blood Glucose, Body Weight drug effects, Diabetes Mellitus, Type 2 blood, Female, Glycated Hemoglobin analysis, Humans, Hypoglycemic Agents administration & dosage, Japan, Male, Middle Aged, Sorbitol administration & dosage, Sorbitol therapeutic use, Treatment Outcome, Weight Loss drug effects, Diabetes Mellitus, Type 2 drug therapy, Hypoglycemic Agents therapeutic use, Sorbitol analogs & derivatives
- Abstract
Luseogliflozin, a selective sodium glucose cotransporter 2 inhibitor, was demonstrated in a previous 24-week study of type 2 diabetic patients to be efficacious and well tolerated. This study mainly aimed to evaluate the long-term safety of luseogliflozin monotherapy in Japanese type 2 diabetic patients based on the Japanese guidelines. Additionally, long-term efficacy was also evaluated. Patients on diet and exercise therapy alone with an HbA1c of 6.9-10.5% received luseogliflozin 2.5 mg once daily for 52 weeks. For patients with insufficient glycemic control, this dose was able to be increased to 5 mg at Week 24. Adverse events (AEs), clinical laboratory tests, vital signs and 12-lead electrocardiograms were used to assess safety. Efficacy endpoints consisted of changes in HbA1c, fasting plasma glucose (FPG), and body weight from baseline. Of 299 patients who received luseogliflozin, 279 completed the study. Most AEs were mild in severity with incidences of AEs and adverse drug reactions at 75.3% and 16.7%, respectively. Although hypoglycemia was observed in 7 patients (2.3%), no major hypoglycemic episodes occurred. The incidences of AEs of special interest, including pollakiuria, volume depletion and urinary tract/genital infections, were at acceptable levels. Luseogliflozin significantly lowered HbA1c (-0.50%, P< 0.001), FPG (-16.3 mg/dL, P< 0.001) and body weight (-2.68 kg, P< 0.001) at Week 52 compared to baseline. Up-titration to 5 mg further improved glycemic control. In this long-term study of Japanese type 2 diabetic patients, luseogliflozin monotherapy was well tolerated for 52 weeks and provided a sustained glycemic lowering effect and reduced body weight.
- Published
- 2015
- Full Text
- View/download PDF
41. Predictive value of SUV-based parameters derived from pre-treatment (18)F-FLT PET/CT for short-term outcome with head and neck cancers.
- Author
-
Hoshikawa H, Yamamoto Y, Mori T, Kishino T, Fukumura T, Samukawa Y, Mori N, and Nishiyama Y
- Subjects
- Aged, Aged, 80 and over, Carcinoma, Squamous Cell diagnosis, Carcinoma, Squamous Cell therapy, Female, Follow-Up Studies, Head and Neck Neoplasms diagnosis, Head and Neck Neoplasms therapy, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Multimodal Imaging methods, Prognosis, Squamous Cell Carcinoma of Head and Neck, Tumor Burden, Carcinoma, Squamous Cell diagnostic imaging, Dideoxynucleosides, Head and Neck Neoplasms diagnostic imaging, Positron-Emission Tomography methods, Radiopharmaceuticals, Tomography, X-Ray Computed methods
- Abstract
Objective: The aim of this study was to investigate the predictive potential of pre-treatment 3'-deoxy-3'-[18F]-fluorothymidine (FLT) uptake parameters for short-term outcome of primary head and neck squamous cell cancer (HNSCC) patients., Patients and Methods: A total of 32 patients undergoing pre-treatment FLT positron emission tomography/computed tomography (PET/CT) from May 2010 to May 2013 were evaluated. Semi-quantitative assessment was used to determine mean, peak and maximum standardized uptake values (SUVmean, SUVpeak and SUVmax), metabolic tumor volume (MTV) and total lesion proliferation (TLP). Clinicopathologic factors and PET/CT parameters were analyzed for their association with 2-year loco-regional control (LRC) and overall survival (OS)., Results: The mean (± SD) SUVmean, SUVpeak, SUVmax, MTV and TLP were 5.97 ± 3.16, 6.71 ± 3.75, 10.05 ± 5.37, 7.31 ± 8.05 and 44.95 ± 52.82, respectively. In univariate analyses, N category was associated with OS (P = 0.037). Increased MTV ≥13 ml was associated with decreased LRC and OS (P < 0.0001). TLP ≥69.3 g was also linked with both LRC and OS (P = 0.009 and 0.015, respectively). Regarding SUVs, only the SUVpeak was associated with LRC and OS (P = 0.035 and 0.049, respectively)., Conclusions: Pre-treatment MTV is the most useful parameter with FLT PET/CT. TLP and SUVpeak may also provide important prognostic information for patients with HNSCCs.
- Published
- 2014
- Full Text
- View/download PDF
42. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria.
- Author
-
Chino Y, Samukawa Y, Sakai S, Nakai Y, Yamaguchi J, Nakanishi T, and Tamai I
- Subjects
- Adult, Animals, Biological Transport drug effects, Biological Transport physiology, Biomarkers blood, Dose-Response Relationship, Drug, Female, Glucose toxicity, Glycosuria chemically induced, Humans, Kidney Tubules drug effects, Male, Sorbitol pharmacology, Xenopus laevis, Young Adult, Glycosuria metabolism, Kidney Tubules metabolism, Sodium-Glucose Transporter 2 metabolism, Sodium-Glucose Transporter 2 Inhibitors, Sorbitol analogs & derivatives, Uric Acid blood
- Abstract
Sodium glucose cotransporter 2 (SGLT2) inhibitors have been reported to lower the serum uric acid (SUA) level. To elucidate the mechanism responsible for this reduction, SUA and the urinary excretion rate of uric acid (UE(UA)) were analysed after the oral administration of luseogliflozin, a SGLT2 inhibitor, to healthy subjects. After dosing, SUA decreased, and a negative correlation was observed between the SUA level and the UE(UA), suggesting that SUA decreased as a result of the increase in the UE(UA). The increase in UE(UA) was correlated with an increase in urinary D-glucose excretion, but not with the plasma luseogliflozin concentration. Additionally, in vitro transport experiments showed that luseogliflozin had no direct effect on the transporters involved in renal UA reabsorption. To explain that the increase in UE(UA) is likely due to glycosuria, the study focused on the facilitative glucose transporter 9 isoform 2 (GLUT9ΔN, SLC2A9b), which is expressed at the apical membrane of the kidney tubular cells and transports both UA and D-glucose. It was observed that the efflux of [(14) C]UA in Xenopus oocytes expressing the GLUT9 isoform 2 was trans-stimulated by 10 mm D-glucose, a high concentration of glucose that existed under SGLT2 inhibition. On the other hand, the uptake of [(14) C]UA by oocytes was cis-inhibited by 100 mm D-glucose, a concentration assumed to exist in collecting ducts. In conclusion, it was demonstrated that the UE(UA) could potentially be increased by luseogliflozin-induced glycosuria, with alterations of UA transport activity because of urinary glucose., (© 2014 The Authors. Biopharmaceutics & Drug Disposition. Published by John Wiley & Sons Ltd.)
- Published
- 2014
- Full Text
- View/download PDF
43. A Strategy for assessing potential drug-drug interactions of a concomitant agent against a drug absorbed via an intestinal transporter in humans.
- Author
-
Mizuno-Yasuhira A, Nakai Y, Gunji E, Uchida S, Takahashi T, Kinoshita K, Jingu S, Sakai S, Samukawa Y, and Yamaguchi J
- Subjects
- 1-Deoxynojirimycin analogs & derivatives, 1-Deoxynojirimycin metabolism, Animals, CHO Cells, Cell Line, Computer Simulation, Cricetulus, Humans, Male, Membrane Transport Proteins metabolism, Models, Biological, Rats, Rats, Sprague-Dawley, Sodium-Glucose Transporter 1 metabolism, Sorbitol analogs & derivatives, Sorbitol metabolism, Drug Interactions physiology, Intestinal Absorption physiology, Intestinal Mucosa metabolism
- Abstract
A strategy for assessing potential drug-drug interactions (DDIs) based on a simulated intestinal concentration is described. The proposed prediction method was applied to the DDI assessment of luseogliflozin, a novel antidiabetic drug, against miglitol absorbed via the intestinal sodium-glucose cotransporter 1 (SGLT1). The method involves four steps: collection of physicochemical and pharmacokinetic parameters of luseogliflozin for use in a computer simulation; evaluation of the validity of these parameters by verifying the goodness of fit between simulated and observed plasma profiles; simulation of the intestinal luseogliflozin concentration-time profile using the Advanced Compartment Absorption and Transit (ACAT) model in a computer program and estimation of the time spent above a value 10-fold higher than the IC50 value (TAIC) for SGLT1; and evaluation of the DDI potential of luseogliflozin by considering the percentage of TAIC against the miglitol Tmax (time for Cmax) value (TAIC/Tmax). An initial attempt to prove the validity of this method was performed in rats. The resulting TAIC/Tmax in rats was 32%, suggesting a low DDI potential of luseogliflozin against miglitol absorption. The validity was then confirmed using an in vivo interaction study in rats. In humans, luseogliflozin was expected to have no DDI potential against miglitol absorption, since the TAIC/Tmax in humans was lower than that in rats. This prediction was proven, as expected, in a clinical interaction study. In conclusion, the present strategy based on a simulation of the intestinal concentration-time profile using dynamic modeling would be useful for assessing the clinical DDI potential of a concomitant agent against drugs absorbed via an intestinal transporter., (Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.)
- Published
- 2014
- Full Text
- View/download PDF
44. Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study.
- Author
-
Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, and Samukawa Y
- Subjects
- Adult, Aged, Asian People, Biomarkers blood, Blood Glucose metabolism, Diabetes Mellitus, Type 2 blood, Diabetes Mellitus, Type 2 ethnology, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Glycated Hemoglobin metabolism, Humans, Hypoglycemic Agents therapeutic use, Japan, Male, Middle Aged, Sorbitol administration & dosage, Sorbitol therapeutic use, Treatment Outcome, Weight Loss, Diabetes Mellitus, Type 2 drug therapy, Hypoglycemic Agents administration & dosage, Sorbitol analogs & derivatives
- Abstract
Objectives: Luseogliflozin is a selective sodium glucose cotransporter 2 inhibitor under development for the treatment of type 2 diabetes mellitus (T2DM). This phase II study was conducted to confirm the efficacy and safety of luseogliflozin monotherapy at doses of up to 10 mg in Japanese patients with T2DM., Patients and Methods: Patients with hemoglobin A1c (HbA1c) of 6.9-10.5% on diet therapy were randomized in a double-blind manner to treatment with 1, 2.5, 5, or 10 mg luseogliflozin or placebo for 12 weeks (n = 56, 56, 54, 58, and 58, respectively)., Trial Registration: Japan Pharmaceutical Information Center (identifier: Japic CTI-101191)., Main Outcome Measures: The primary endpoint was the change in HbA1c from baseline to the end of treatment. Other endpoints included fasting plasma glucose (FPG), postprandial plasma glucose (PPG) and body weight. Adverse events were recorded throughout the study., Results: HbA1c decreased significantly at the end of treatment in the 1, 2.5, 5, and 10 mg luseogliflozin groups compared with placebo (-0.29, -0.39, -0.46, and -0.43%, respectively, versus +0.22%; all P < 0.001), as did FPG and PPG (all P < 0.001). Body weight also decreased significantly in all luseogliflozin groups compared with placebo (all P < 0.001). The incidence rates of adverse events (40.0-50.0%) were not significantly different among the five groups. The overall incidence of hypoglycemia was low. Limitations of this study include the short study duration and the relatively small sample size., Conclusions: In Japanese patients with T2DM, luseogliflozin was well tolerated, improved glycemic control, and reduced body weight over 12 weeks of treatment at all tested doses. Doses of ≥2.5 mg achieved similar improvements in glycemic control.
- Published
- 2014
- Full Text
- View/download PDF
45. Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study.
- Author
-
Seino Y, Sasaki T, Fukatsu A, Sakai S, and Samukawa Y
- Subjects
- Adult, Aged, Asian People, Biomarkers blood, Diabetes Mellitus, Type 2 blood, Diabetes Mellitus, Type 2 ethnology, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Glycated Hemoglobin metabolism, Humans, Japan, Male, Middle Aged, Sorbitol therapeutic use, Treatment Outcome, Weight Loss, Diabetes Mellitus, Type 2 drug therapy, Hypoglycemic Agents therapeutic use, Sorbitol analogs & derivatives
- Abstract
Objective: Luseogliflozin is a novel sodium glucose cotransporter 2 inhibitor for type 2 diabetes mellitus (T2DM) treatment. An exploratory Phase II study was conducted to assess the efficacy and safety of several doses of luseogliflozin in Japanese T2DM patients., Patients and Methods: Japanese T2DM patients aged 20-74 years with hemoglobin A1c (HbA1c) of 6.9-10.5%, fasting plasma glucose (FPG) ≥126 mg/dL and on diet therapy were randomized in a double-blind manner to receive luseogliflozin (0.5, 2.5, or 5 mg) or placebo once daily for 12 weeks (n = 61, 61, 61, and 56, respectively). The primary endpoint was the change in HbA1c from baseline to end of treatment. Other endpoints included FPG, 2 h postprandial plasma glucose (PPG) in a meal tolerance test (MTT), and body weight. Drug safety was also assessed., Trial Registration: Japan Pharmaceutical Information Center (identifier: JapicCTI-090908)., Results: Changes in HbA1c from baseline to end of treatment were -0.36, -0.62, and -0.75% in the 0.5, 2.5, and 5 mg luseogliflozin groups, respectively, versus +0.06% in the placebo group (all P < 0.001). The reductions in FPG and 2 h-PPG in the MTT were also significantly greater in the luseogliflozin groups (all P < 0.01) without increases in insulin levels from baseline. Luseogliflozin reduced body weight at all doses. There were no significant differences in the incidences of adverse events among groups. Most adverse events were mild in severity. There were no serious adverse events., Conclusions: Although this was a small-scale study with a short duration, all tested doses of luseogliflozin significantly improved glycemic control, reduced body weight, and were well tolerated in Japanese T2DM patients over the 12-week treatment period.
- Published
- 2014
- Full Text
- View/download PDF
46. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study.
- Author
-
Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, and Samukawa Y
- Subjects
- Adult, Aged, Aged, 80 and over, Asian People, Biomarkers blood, Blood Glucose metabolism, Diabetes Mellitus, Type 2 blood, Diabetes Mellitus, Type 2 ethnology, Double-Blind Method, Drug Administration Schedule, Female, Glycated Hemoglobin metabolism, Humans, Japan, Male, Middle Aged, Sorbitol therapeutic use, Treatment Outcome, Weight Loss, Diabetes Mellitus, Type 2 drug therapy, Hypoglycemic Agents therapeutic use, Sorbitol analogs & derivatives
- Abstract
Objective: Luseogliflozin--a novel, orally bioavailable, 1-thio-D-glucitol derivative and a selective sodium glucose cotransporter 2 inhibitor--has shown efficacy and tolerability in previous phase 2 studies. This phase 3, randomized, double-blind, placebo-controlled, comparative study aimed to confirm the superiority of 24 week luseogliflozin 2.5 mg monotherapy over placebo in reducing hemoglobin A1c (HbA1c) levels in Japanese patients with type 2 diabetes mellitus (T2DM)., Methods: Patients with HbA1c levels of 6.9%-10.5% were randomized to receive luseogliflozin 2.5 mg or placebo once daily for 24 weeks (n = 79 in each group). The primary endpoint was change from baseline in HbA1c at end of treatment. Secondary endpoints included change from baseline in fasting plasma glucose (FPG) and postprandial plasma glucose (PPG) following a meal tolerance test, body weight, and abdominal circumference. Safety assessments included adverse events (AEs), clinical laboratory tests, and vital signs., Results: At the end of treatment, HbA1c was significantly decreased from baseline in the luseogliflozin 2.5 mg group (-0.63%) versus the placebo group (0.13%), with a between-group difference of -0.75% (p < 0.001). Additionally, significant reductions in FPG, PPG, body weight, and abdominal circumference were noted with luseogliflozin compared with placebo (all p < 0.05). Luseogliflozin was well tolerated; there was no significant difference between groups in the incidence of AEs (luseogliflozin, 59.5%; placebo, 57.0%). No AEs led to study drug discontinuation. Most AEs were mild in severity, with no severe AE reported. Limitations of this study include its short study duration and small sample size., Conclusion: Luseogliflozin monotherapy for 24 weeks was superior to placebo in reducing HbA1c levels. It also reduced FPG, PPG, body weight, and abdominal circumference and was well tolerated in Japanese patients with T2DM., Clinical Trial Registration: JapicCTI-111661.
- Published
- 2014
- Full Text
- View/download PDF
47. Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial.
- Author
-
Sasaki T, Seino Y, Fukatsu A, Sakai S, and Samukawa Y
- Subjects
- Adult, Dose-Response Relationship, Drug, Drug Administration Schedule, Half-Life, Humans, Hypoglycemic Agents pharmacokinetics, Japan, Male, Single-Blind Method, Sorbitol pharmacokinetics, Sorbitol pharmacology, Young Adult, Blood Glucose drug effects, Diabetes Mellitus, Type 2 drug therapy, Glycosuria chemically induced, Hypoglycemic Agents pharmacology, Sorbitol analogs & derivatives
- Abstract
Introduction: Luseogliflozin, a sodium glucose cotransporter 2 inhibitor, inhibits reabsorption of glucose in the proximal renal tubule. It was developed for the treatment of type 2 diabetes mellitus., Methods: For this first human study of luseogliflozin, randomized, single-blind, placebo-controlled, single ascending dose (1-25 mg) and multiple ascending dose (5 or 10 mg/day, 7 days) trials were conducted in healthy male Japanese subjects to investigate safety, pharmacokinetics, and pharmacodynamics., Results: There were no serious adverse events, adverse events leading to discontinuation, or episodes of hypoglycemia. After administration of a single oral dose of luseogliflozin, its maximum plasma level (C max) and area under the concentration-time curve increased in a dose-dependent manner, and no food effects were observed on pharmacokinetics. The mean time taken to reach C max (T max) ranged from 0.667 to 2.25 h. The mean plasma half-life of luseogliflozin (T 1/2) after multiple dosing for 7 days ranged from 9.14 to 10.7 h, and no detectable accumulation of luseogliflozin was observed. Urinary glucose excretion increased in a dose-dependent manner, ranging from 18.9 to 70.9 g (single-dose study)., Conclusion: Luseogliflozin was well tolerated and showed favorable pharmacokinetic and pharmacodynamic profiles in healthy male Japanese subjects.
- Published
- 2014
- Full Text
- View/download PDF
48. Blindness caused by septic superior ophthalmic vein thrombosis in a Lemierre Syndrome variant.
- Author
-
Akiyama K, Karaki M, Samukawa Y, and Mori N
- Subjects
- Aged, Anti-Bacterial Agents therapeutic use, Cellulitis complications, Cellulitis drug therapy, Eye blood supply, Face, Humans, Lemierre Syndrome drug therapy, Male, Multiple Pulmonary Nodules, Orbit blood supply, Orbital Cellulitis drug therapy, Pulmonary Embolism, Tomography, X-Ray Computed, Venous Thrombosis drug therapy, Blindness etiology, Lemierre Syndrome complications, Orbital Cellulitis complications, Venous Thrombosis etiology
- Abstract
A 65-year-old man presented with right facial cellulitis and right blindness. Enhanced CT and MRI showed right facial cellulitis involved with pterigopalatine fossa. Additionally, orbital cellulitis, superior ophthalmic vein thrombosis, and pulmonary multiple nodules were observed. (18)F-FDG PET/CT supported these findings. He was diagnosed with septic superior ophthalmic vein thrombosis accompanied with Lemierre Syndrome variant and was treated mainly by the administration of intravenous antibiotics. His symptoms and image findings improved after a few days of treatment, but the right visual loss has not recovered. Since septic superior ophthalmic vein thrombosis and Lemierre Syndrome both have life-threatening potential, early diagnosis and appropriate treatment are important and may contribute to reduce the incidence of severe complications. Septic superior ophthalmic vein thrombosis accompanied with Lemierre Syndrome is exceeding rare, and this case is the first report of blindness in Lemierre Syndrome. A literature review and discussion of septic superior ophthalmic vein thrombosis and Lemierre Syndrome are included., (Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.